Previous 10 | Next 10 |
Study results show TUSC2 overexpression decreased thyroid cancer tumor metastasis and increased sensitivity to apoptosis by increasing SMAC/DIABLO and Cytochrome C protein levels Study highlights the possibility that TUSC2 may also be effective in thyroid cancer therapy and adds to...
Ocean Bio-Chem (NASDAQ: OBCI ) +80% as its subsidiary Star brite announces registered EPA product kills the Coronavirus . More news on: Ocean Bio-Chem, Inc., Happiness Biotech Group Limited, Delphi Technologies PLC, Stocks on the move, , Read more ...
Capital raise follows recent Fast Track Designation by the FDA for Company’s Oncoprex™ imunogene therapy for NSCLC in combination therapy with AstraZeneca’s Tagrisso® Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a ...
NeuroMetrix (NASDAQ: NURO ) -33% on Q4 results . More news on: NeuroMetrix, Inc., NIO Limited, Genprex, Inc., Stocks on the move, , Read more ...
Genprex, Inc. ( GNPX ) has been on an outstanding two-day run since it announced that the FDA has granted Fast Track Designation for its Oncoprex immunogene therapy in combination with AstraZeneca's ( AZN ) Tagrisso for certain non-small cell lung cancer patients. The stock has risen from ...
Gainers: Trans World Entertainment TWMC +260% . More news on: Kaleido BioSciences, Inc., SLM Corporation, Bat Group, Inc., , , Stocks on the move Read more ...
Genprex (NASDAQ: GNPX) , a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced its entry into securities purchase agreements wit...
Genprex (NASDAQ: GNPX ) -37% on pricing $8M stock offering. More news on: Genprex, Inc., Applied Genetic Technologies Corporation, Tetraphase Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform,...
Gainers: Neurotrope (NASDAQ: NTRP ) +126% . More news on: Neurotrope, Inc., Genprex, Inc., Trillium Therapeutics Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNe...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...